A trial published in the New England Journal of Medicine found that participants using tirzepatide lost up to 20.9% of their body weight over 72 weeks, with outcomes improving at higher doses across all treatment groups (Jastreboff et al., NEJM, 2022, Washington residents across the state, from Seattle to Spokane and everywhere in between, have real and practical access to tirzepatide today
Healthcare professionals should counsel patients that proven lifestyle modifications and medical treatments offer the only validated approaches to managing fatty liver disease
a single-dose 7.2mg pen is under EU review
Most cases result from dehydration caused by the medication's gastrointestinal effectsparticularly nausea, vomiting, and diarrhoeawhich lead to concentrated urine appearing darker in colour
At 1.7mg, approximately 38% experience GI symptoms, 2% notice hair loss onset, and gallbladder risk is about 0.8%